China Largest Manufacturer factory Supply Bimatoprost CAS 155206-00-1

Superiority:

                                PRODUCT DETAILS       

Bimatoprost Basic information Glaucoma Drug Side effects Glaucoma commonly used drugs Bimatoprost - timolol maleate compound eye drops Product Name: Bimatoprost Synonyms: N-ETHYL-9ALPHA,11ALPHA,15S-TRIHYDROXY-17-PHENYL-18,19,20-TRINOR-PROSTA-5Z, 13E-DIEN-1-AMIDE;LUMIGAN;BIMATOPROST;BIMATOPROST(TM);17-PHENYL TRINOR PROSTAGLANDIN F2ALPHA ETHYL AMIDE;BIMATOPROST(LUMIGAN);17-phenyl-tri-norprostaglandin f2α-ethyl amide;(Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide CAS: 155206-00-1 MF: C25H37NO4 MW: 415.57 EINECS: 642-890-9 Product Categories: API;Prostaglandin;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals;Arachidonic Acid Cascade;Prostaglandins;Lipids in Cell Signaling;Lumigan;Inhibitors;Benzotriazoles ,Others ,Benzoxazines;pharmaceutical intermediate Mol File: 155206-00-1.mol   Bimatoprost Chemical Properties Melting point  66-68°C Boiling point  629.8±55.0 °C(Predicted) density  1.145±0.06 g/cm3(Predicted) storage temp.  -20°C solubility  Chloroform (Slightly), Dichloromethane (Slightly), Methanol (Slightly) form  solid pka 14.25±0.20(Predicted) color  White to Off-White Stability: Light Sensitive InChIKey AQOKCDNYWBIDND-FTOWTWDKSA-N CAS DataBase Reference 155206-00-1(CAS DataBase Reference)   Safety Information WGK Germany  3 MSDS Information Provider Language SigmaAldrich English   Bimatoprost Usage And Synthesis Glaucoma Drug Bimatoprost is a synthetic amide F2α derivative ,it can selectively simulate the effect forefront amines produced by the body, which make aqueous humor production rate increase aqueous outflow resistance is reduced, by increasing the amount of aqueous outflow of the uveoscleral and trabecular Netcom channel to reduce intraocular pressure (IOP),it is considered to be the most effective hypotensive drug of topical ocular anti-glaucoma drugs,it is suitable for the treatment of open-angle glaucoma (POAG) or invalid elevated intraocular other ocular hypotensive medications compression syndrome (OHT) patients. Side effects 1. to deepen the color of the iris, blepharitis, eye irritation and pain; black eyelashes thicker growth; conjunctival hyperemia, temporarily punctate corneal epithelial erosion, eyelid edema and erythema; rash. 2. rare respiratory disorders, asthma exacerbations, iritis, uveitis, eyelid skin darkening. 3. very rare chest pain, pharyngitis. 4. eye itching, allergic conjunctivitis, cataract, conjunctival edema, secretions, photophobia, superficial punctate keratitis, headache, high blood pressure. Glaucoma commonly used drugs 1. prostaglandin derivatives such as latanoprost (Xalatan), bimatoprost (trade name Lumigan) and travoprost (Travatan) can increase outflow of aqueous humor uveoscleral . Bimatoprost also increases trabecular outflow. 2. topical β-adrenergic such as timolol, levobunolol (Betagan), and betaxolol can decrease receptor antagonist of aqueous humor production of ciliary body . 3. Alpha2-adrenergic agonists such as brimonidine (Alphagan) with dual working mechanism, can reduce aqueous humor production and increase trabecular outflow. 4. one case of the selective reduction similar to epinephrine and dipivefrin (Propine) increase outflow of aqueous humor through trabecular meshwork and possibly through uveoscleral outflow pathway, probably by a β2-agonist action. 5. miotic agents (parasympathomimetics), if ciliary muscle contraction Roca works, it can tighten the trabecular and allow increaseing outflow of aqueous humor. Ecothiopate is used for chronic glaucoma. 6. dorzolamide (Trusopt), brinzolamide (Azopt), by inhibiting carbonic anhydrase acetazolamide of ciliary body, reduce aqueous humor secretion of carbonic anhydrase inhibitors. 7. Physostigmine is also used to treat glaucoma and delayed gastric emptying. The above information is edited by the Chemicalbook of Tian Ye. Bimatoprost - timolol maleate compound eye drops In July 2006 , bimatoprost-timolol maleate compound eye drops developed by the United States company obtained approval from the European drug regulatory authority for reducing intraocular pressure or ocular hypertension of open-anglepatients glaucoma patients who do not respond adequately to the β-blockers or prostaglandin like treatment . The compound eye drops containing 0.03% bimatoprost and 0.5% timolol maleate, once a day administration is able to provide clinically effective pressure control, the effect is better than single Bima latanoprost or timolol maleate. Clinical trials prove that the drug has an excellent tolerability, including the incidence of ocular hyperemia40% lower compared to single bimatoprost . Description Bimatoprost was first introduced in the US and Brazil as Lumigan , an ophthalmic solution (0.03%) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, a proven risk of glaucomatous visual field loss. Bitamoprost is a new agent belonging to the PGF2α analog class of prostamides launched in this indication after latanoprost, the most efficaceous topical medication currently available. This synthetic fatty acid amide can be prepared by esterification of 17- phenyl-18,19,20-trinorprostaglandin F2α followed by ethylamidation. Bimatoprost, as related prostamides, is devoid of typical activities associated with PGF2,, analogs; it exhibits a unique pharmacological profile in contracting the feline iris sphincter with an EC50 of 34 nM without interacting with any known prostanoid receptors. Thus it mimics the action of endogenous prostamides on specific receptors that lower IOP by increasing aqueous humor outflow through both pressure-insensitive and pressure-sensitive pathways without reducing humor formation. In a 3-month controlled clinical trial of efficacy and safety in patients with elevated IOP, bimatoprost demonstrated lower mean intraocular pressures at every time point throughout the study, as well as a good tolerance and systemic safety profile compared to latanoprost. Chemical Properties Crystalline Solid Originator Allergan (US) Uses Antiglaucoma. Synthetic prostamide; structurally related to prostaglandin F2a. Uses Antiglaucoma. Synthetic prostamide; structurally related to prostaglandin F2α. Uses Bimatoprost is a prostaglandin analog used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension. It reduces intraocular pressure (IOP) by increasing the outflow of aqueous fluid from the eyes. It ha Uses Bimatoprost is an antiglaucoma agent. Bimatoprost is an synthetic prostamide; structurally related to prostaglandin F2α. Uses 17-phenyl trinor Prostaglandin F2α ethyl amide (17-phenyl trinor PGF2α ethyl amide) is an F-series PG analog which has been approved for use as an ocular hypotensive drug. Investigations in our lab have shown that 17-phenyl trinor PGF2α ethyl amide is converted by an amidase enzymatic activity in the bovine and human cornea to yield the corresponding free acid, with a conversion rate of about 40 μg/g corneal tissue/24 hours. The free acid, 17-phenyl trinor PGF2α, is a potent FP receptor agonist. In human and animal models of glaucoma, FP receptor agonist activity corresponds very closely with intraocular hypotensive activity.[Cayman Chemical] Brand name Lumigan (Allergan). General Description Bimatoprost (Lumigan) is supplied as a sterile 0.03%ophthalmic solution in 2.5- and 5.0-mL sizes. The recommendeddosage of bimatoprost is limited to one drop intothe affected eye once daily in the evening. Increased usagemay decrease its beneficial effect. If used concurrently withother IOP-lowering drugs, a waiting period of 5 minutesshould separate administrations.   Bimatoprost Preparation Products And Raw materials Preparation Products (5E)-BiMatoprost

                                                                         About US 

Leader Biochemical Group is a large leader incorporated industry manufacturers and suppliers of advanced refined raw materials From the year of 1996 when our factory was put into production to year of 2020, our group has successively invested in more than 52 factories with shares and subordinates.We focus on manufacture Pharm & chemicals, functional active ingredients, nutritional Ingredients, health care products, cosmetics, pharmaceutical and refined feed, oil, natural plant ingredients industries to provide top quality of GMP standards products.All the invested factories' product lines cover API and intermediates, vitamins, amino acids, plant extracts, daily chemical products, cosmetics raw materials, nutrition and health care products, food additives, feed additives, essential oil products, fine chemical products and agricultural chemical raw materials And flavors and fragrances. Especially in the field of vitamins, amino acids, pharmaceutical raw materials and cosmetic raw materials, we have more than 20 years of production and sales experience. All products meet the requirements of high international export standards and have been recognized by customers all over the world. Our manufacture basement & R&D center located in National Aerospace Economic & Technical Development Zone Xi`an Shaanxi China. Now not only relying on self-cultivation and development as well as maintains good cooperative relations with many famous research institutes and universities in China. Now, we have closely cooperation with Shanghai Institute of Organic Chemistry of Chinese Academy of Science, Beijing Institute of Material Medical of Chinese Academy of Medical Science, China Pharmaceutical University, Zhejiang University. Closely cooperation with them not only integrating Science and technology resources, but also increasing the R&D speed and improving our R&D power. Offering Powerful Tech supporting Platform for group development. Keep serve the manufacture and the market as the R&D central task, focus on the technical research.  Now there are 3 technology R & D platforms including biological extract, microorganism fermentation and chemical synthesis, and can independently research and develop kinds of difficult APIs and pharmaceutical intermediates. With the strong support of China State Institute of Pharmaceutical Industry (hereinafter short for CSIPI), earlier known as Shanghai Institute of Pharmaceutical Industry (SIPI), we have unique advantages in the R & D and industrialization of high-grade, precision and advanced products.  Now our Group technical force is abundant, existing staff more that 1000 people, senior professional and technical staff accounted for more than 50% of the total number of employees, including 15 PhD research and development personnel, 5 master′ S degree in technical and management personnel 9 people. We have advanced equipment like fermentation equipment and technology also extraction, isolation, purification, synthesis with rich production experience and strict quality control system, According to the GMP required, quickly transforming the R&D results to industrial production in time, it is our advantages and our products are exported to North and South America, Europe, Middle East, Africa, and other five continents and scale the forefront in the nation, won good international reputation.  We believe only good quality can bring good cooperation, quality is our key spirit during our production, we are warmly welcome clients and partner from all over the world contact us for everlasting cooperation, Leader will be your strong, sincere and reliable partner in China.

                                                                       Group profiles

Our Factories production lines

                                                   Our Factories R&D ability

                        Our Factories warehouse